{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:47:33Z","timestamp":1792205253011,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ijid.2017.05.003","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T19:30:57Z","timestamp":1494271857000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis"],"prefix":"10.1016","volume":"60","author":[{"given":"Ping","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2017.05.003_bib0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00003495-200059010-00010","article-title":"Moxifloxacin","volume":"59","author":"Balfour","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2017.05.003_bib0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/rccm.200603-360OC","article-title":"Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis","volume":"174","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2017.05.003_bib0015","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tube.2015.03.014","article-title":"Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: a meta-analysis","volume":"95","author":"Chen","year":"2015","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijid.2017.05.003_bib0020","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial","volume":"373","author":"Conde","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2017.05.003_bib0025","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","volume":"385","author":"Dawson","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2017.05.003_bib0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.200901-0078OC","article-title":"Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis","volume":"180","author":"Dorman","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2017.05.003_bib0035","first-page":"437","article-title":"Low access to a highly effective therapy: a challenge for international tuberculosis control","volume":"80","author":"Dye","year":"2002","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ijid.2017.05.003_bib0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijid.2015.01.014","article-title":"The complex evolution of antibiotic resistance in Mycobacterium tuberculosis","volume":"32","author":"Fonseca","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2017.05.003_bib0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jac\/44.3.393","article-title":"Activity of moxifloxacin against mycobacteria","volume":"44","author":"Gillespie","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2017.05.003_bib0050","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2017.05.003_bib0055","doi-asserted-by":"crossref","first-page":"e67030","DOI":"10.1371\/journal.pone.0067030","article-title":"Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients","volume":"8","author":"Jawahar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2017.05.003_bib0060","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.42.8.2066","article-title":"In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis","volume":"42","author":"Ji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.05.003_bib0065","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2017.05.003_bib0070","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2165\/00003495-200464200-00006","article-title":"Moxifloxacin","volume":"64","author":"Keating","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2017.05.003_bib0075","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1128\/AAC.45.12.3482-3486.2001","article-title":"Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice","volume":"45","author":"Lounis","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.05.003_bib0080","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2017.05.003_bib0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/AAC.43.1.85","article-title":"Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis","volume":"43","author":"Miyazaki","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.05.003_bib0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1742-1241.2011.02839.x","article-title":"Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials","volume":"66","author":"Mu","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijid.2017.05.003_bib0095","first-page":"128","article-title":"A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2017.05.003_bib0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/cir772","article-title":"Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome","volume":"54","author":"Seddon","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.05.003_bib0105","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1185\/03007990903223663","article-title":"Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines","volume":"25","author":"Simoens","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijid.2017.05.003_bib0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tube.2015.02.037","article-title":"Fluoroquinolones for the treatment of tuberculosis in children","volume":"95","author":"Thee","year":"2015","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijid.2017.05.003_bib0115","first-page":"401","article-title":"WHO global tuberculosis control report 2009: tuberculosis elimination is a distant dream","volume":"46","author":"Vashishtha","year":"2009","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.ijid.2017.05.003_bib0120","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/cid\/ciu550","article-title":"Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India","volume":"59","author":"Velayutham","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.05.003_bib0125","doi-asserted-by":"crossref","first-page":"e29588","DOI":"10.1371\/journal.pone.0029588","article-title":"Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotype","volume":"7","author":"Visser","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2017.05.003_bib0130","first-page":"65","article-title":"Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis","volume":"14","author":"Wang","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2017.05.003_bib0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat Rev Drug Discov"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121730139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121730139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T22:01:38Z","timestamp":1569276098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197121730139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":27,"alternative-id":["S120197121730139X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2017.05.003","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2017.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}